[Clinical-Biological analyses and electrocardiographic follow-up of 104 cases of plasmodium falciparum malaria treated at Camp Kosseï in N'Djamena (Tchad)].
暂无分享,去创建一个
F. Pons | G. Cellarier | Natacha Gantois | Rhiannon Howe | Dorian Cellarier | Marion Rebardy | Jessica Paez | Sarah Rommel | Carmelo Moscato | Eléna Labourdere
[1] E. Javelle,et al. Treatment for Uncomplicated Plasmodium falciparum Malaria in French Soldiers Deployed in Sub-Saharan Africa: Gaps Between Policy and Field Practice. , 2018, Military medicine.
[2] Q. Bassat,et al. Efficacy and Tolerability Outcomes of a Phase II, Randomized, Open-Label, Multicenter Study of a New Water-Dispersible Pediatric Formulation of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in African Infants , 2017, Antimicrobial Agents and Chemotherapy.
[3] G. Dolo,et al. Entomological and parasitological parameters of malaria transmission in Douguia, Chad. , 2017, Medecine et sante tropicales.
[4] F. Binka,et al. Post-licensure safety evaluation of dihydroartemisinin piperaquine in the three major ecological zones across Ghana , 2017, PloS one.
[5] S. Abdulla,et al. Multi-Country Evaluation of Safety of Dihydroartemisinin/Piperaquine Post-Licensure in African Public Hospitals with Electrocardiograms , 2016, PloS one.
[6] S. Abdulla,et al. Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania , 2015, Malaria Journal.
[7] Organización Mundial de la Salud. Guidelines for the treatment of malaria , 2010 .
[8] Q. Bassat,et al. Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine for Treating Uncomplicated Malaria in African Children: A Randomised, Non-Inferiority Trial , 2009, PloS one.
[9] N. White. Cardiotoxicity of antimalarial drugs. , 2007, The Lancet. Infectious diseases.